#BEGIN_DRUGCARD DB00193

# AHFS_Codes:
28:08.08

# ATC_Codes:
N02AX02

# Absorption:
Racemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%.The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults.

# Biotransformation:
The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models.

# Brand_Mixtures:
Not Available

# Brand_Names:
Crispin
Ralivia ER
Ralivia Flashtab
Tramadol HCl BP/EP
Tramal
Tridural
Ultram
Ultram ER

# CAS_Registry_Number:
27203-92-5

# ChEBI_ID:
Not Available

# Chemical_Formula:
C16H25NO2

# Chemical_IUPAC_Name:
(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A narcotic analgesic proposed for moderate to severe pain. It may be habituating. [PubChem]

# Dosage_Forms:
Tablet, extended release	Oral

# Drug_Category:
Analgesics
Analgesics, Opioid
Narcotics

# Drug_Interactions:
Almotriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Alvimopan	Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
Aminoglutethimide	Aminoglutethimide may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Amiodarone	Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production.
Amitriptyline	Tramadol increases the risk of serotonin syndrome and seizures.
Amoxapine	Tramadol increases the risk of serotonin syndrome and seizures.
Amprenavir	Amprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Aprepitant	Aprepitant may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Atazanavir	Atazanavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Benzphetamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Bosentan	Bosentan may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Bromocriptine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Cabergoline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Carbamazepine	Carbamazepine may decrease the effect of tramadol by increasing Tramadol metabolism and clearance.
Chloroquine	Chloroquine may decrease the effect of Tramadol by decreasing active metabolite production.
Chlorpromazine	Chlorpromazine may decrease the effect of Tramadol by decreasing active metabolite production.
Cimetidine	Cimetidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Cimetidine may decrease the effect of Tramadol by decreasing active metabolite production.
Cinacalcet	Cinacalcet may decrease the effect of Tramadol by decreasing active metabolite production.
Citalopram	The use of two serotonin modulators, such as citalopram and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Clarithromycin	Clarithromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Clomipramine	Tramadol increases the risk of serotonin syndrome and seizures. Clomipramine may decrease the effect of Tramadol by decreasing active metabolite production.
Clotrimazole	Clotrimazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Clozapine	Clozapine may decrease the effect of Tramadol by decreasing active metabolite production.
Cocaine	Cocaine may decrease the effect of Tramadol by decreasing active metabolite production.
Conivaptan	Conivaptan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Cyclobenzaprine	Increases risk of seizure.
Cyclosporine	Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Darifenacin	Darifenacin may decrease the effect of Tramadol by decreasing active metabolite production.
Darunavir	Darunavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Delavirdine	Delavirdine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Delavirdine may decrease the effect of Tramadol by decreasing active metabolite production.
Desipramine	Tramadol increases the risk of serotonin syndrome and seizures. Desipramine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Desipramine may decrease the effect of Tramadol by decreasing active metabolite production.
Desvenlafaxine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Dexamethasone	Dexamethasone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Dextroamphetamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Dextromethorphan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Dihydroergotamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Diltiazem	Diltiazem may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Diphenhydramine	Diphenhydramine may decrease the effect of Tramadol by decreasing active metabolite production.
Doxepin	Tramadol increases the risk of serotonin syndrome and seizures.
Duloxetine	Duloxetine may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.
Efavirenz	Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Eletriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Ergoloid mesylate	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Ergonovine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Ergotamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Erythromycin	Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Escitalopram	Tramadol may increase the risk of serotonin syndrome and seizures.
Etravirine	Tramadol,when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration and efficacy due to increased tramadol metabolism and clearance.
Fluconazole	Fluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Fluoxetine	The use of two serotonin modulators, such as fluoxetine and tramadol, may increase the risk of serotonin syndrome. Fluoxetine may decrease the effect of tramadol by decreasing active metabolite production.
Fluvoxamine	Tramadol may increase the risk of serotonin syndrome and seizures.
Fosamprenavir	Fosamprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Fosphenytoin	Fosphenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Frovatriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Furazolidone	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Furazolidone.
Haloperidol	Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production.
Imatinib	Imatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Imatinib may decrease the effect of Tramadol by decreasing active metabolite production.
Imipramine	Tramadol increases the risk of serotonin syndrome and seizures. Imipramine may decrease the effect of Tramadol by decreasing active metabolite production.
Indinavir	Indinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Isocarboxazid	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid.
Isoniazid	Isoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production.
Itraconazole	Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Ketoconazole	Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production.
Lapatinib	Lapatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Lidocaine	Lidocaine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lidocaine may decrease the effect of Tramadol by decreasing active metabolite production.
Linezolid	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid.
Lisdexamfetamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Lopinavir	Lopinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lopinavir may decrease the effect of Tramadol by decreasing active metabolite production.
Maprotiline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Meperidine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Methadone	Methadone may decrease the effect of Tramadol by decreasing active metabolite production.
Methamphetamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Methotrimeprazine	Additive CNS depressant effects. Decrease dose of tramadol by 50% if initiating methotrimeprazine therapy. Monitor for increased CNS depression and apply further dosage adjustments as required.
Methylergonovine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Metronidazole	Metronidazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Miconazole	Miconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Miconazole may decrease the effect of Tramadol by decreasing active metabolite production.
Mirtazapine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Moclobemide	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide.
Nafcillin	Nafcillin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Naratriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Nefazodone	Nefazodone may increase tramadol toxicity by decreasing tramadol metabolism and clearance. Increased risk of serotonin syndrome. Monitor for tramadol toxicity and symptoms of serotonin syndrome.
Nelfinavir	Nelfinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Nevirapine	Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Nicardipine	Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production.
Nilotinib	Nilotinib may decrease the effect of Tramadol by decreasing active metabolite production.
Norfloxacin	Norfloxacin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Nortriptyline	Tramadol increases the risk of serotonin syndrome and seizures.
Oxcarbazepine	Oxcarbazepine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Paroxetine	Tramadol may increase the risk of serotonin syndrome and seizures. Paroxetine may decrease the effect of Tramadol by decreasing active metabolite production.
Pentobarbital	Pentobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Pergolide	Pergolide may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome.
Phendimetrazine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Phenelzine	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, phenelzine.
Phenobarbital	Phenobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Phentermine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Phenytoin	Phenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Pioglitazone	Pioglitazone may decrease the effect of Tramadol by decreasing active metabolite production.
Posaconazole	Posaconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Primidone	Primidone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Procarbazine	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Procarbazine.
Promethazine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Protriptyline	Tramadol increases the risk of serotonin syndrome and seizures.
Pyrimethamine	Pyrimethamine may decrease the effect of Tramadol by decreasing active metabolite production.
Quinidine	Quinidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Quinidine may decrease the effect of Tramadol by decreasing active metabolite production.
Quinine	Quinine may decrease the effect of Tramadol by decreasing active metabolite production.
Ranolazine	Ranolazine may decrease the effect of Tramadol by decreasing active metabolite production.
Rasagiline	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, rasagiline.
Rifabutin	Rifabutin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Rifampin	Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Rifapentine	Rifapentine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
Ritonavir	Ritonavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ritonavir may decrease the effect of Tramadol by decreasing active metabolite production.
Rizatriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
S-Adenosylmethionine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Saquinavir	Saquinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Selegiline	Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Selegiline.
Sertraline	Tramadol increases the risk of serotonin syndrome and seizures. Sertraline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Sertraline may decrease the effect of Tramadol by decreasing active metabolite production.
Sibutramine	Sibutramine may incrase the serotonergic effect of the Tramadol. Concomitant therapy should be avoided.
Sitaxentan	Sitaxsentan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
St. John's Wort	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Sumatriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Telithromycin	Telithromycin may decrease the metabolism and clearance of tramadol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of tramadol if telithromycin is initiated, discontinued or dose changed.
Terbinafine	Terbinafine may decrease the effect of Tramadol by decreasing active metabolite production.
Tetracycline	Tetracycline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Thioridazine	Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production.
Ticlopidine	Ticlopidine may decrease the effect of Tramadol by decreasing active metabolite production.
Tranylcypromine	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, tranylcypromine. Tranylcypromine may decrease the effect of tramadol by decreasing active metabolite production.
Trazodone	The use of two serotonin modulators, such as trazodone and tramadol, may increase the risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Trimipramine	Tramadol may increase the risk of serotonin syndrome and seizures.
Triprolidine	The CNS depressants, Triprolidine and Tramadol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Venlafaxine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Verapamil	Verapamil may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Voriconazole	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tramadol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tramadol if voriconazole is initiated, discontinued or dose changed.
Zolmitriptan	The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.

# Drug_Reference:
10959067	Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000 Mar-Apr;14(2):65-70.
12855342	Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003 Jul;104(1-2):323-31.
9190321	Dayer P, Desmeules J, Collart L: [Pharmacology of tramadol] Drugs. 1997;53 Suppl 2:18-24.
9190323	Gobel H, Stadler T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine] Drugs. 1997;53 Suppl 2:34-9.
9633738	Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998 Jun;50(6):1842-6.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.4

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble in water.

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Tramadol

# HET_ID:
Not Available

# Half_Life:
23 +/- 10 minutes

# InChI_Identifier:
InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1

# InChI_Key:
InChIKey=TVYLLZQTGLZFBW-ZBFHGGJFSA-N

# Indication:
Indicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.

# KEGG_Compound_ID:
C07153

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
193

# Mechanism_Of_Action:
Tramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors.

# Melting_Point:
180-181 Â°C

# Molecular_Weight_Avg:
263.3752

# Molecular_Weight_Mono:
263.188529049

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451735

# Pharmacology:
Tramadol, a centrally-acting analgesic, exists as a racemic mixture of the <i>trans</i> isomer, with important differences in binding, activity, and metabolism associated with the two enantiomers. Although Tramadol is a synthetic analog of codeine, it has a significantly lower affinity for opioid receptors than codeine.

# Predicted_LogP_Hydrophobicity:
2.71

# Predicted_LogS:
-2.5

# Predicted_Water_Solubility:
7.50e-01 g/l

# Primary_Accession_No:
DB00193

# Protein_Binding:
20%

# PubChem_Compound_ID:
33741

# PubChem_Substance_ID:
46506256

# RxList_Link:
http://www.rxlist.com/cgi/generic/tramadol.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00028

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Tramadol HCl
Tramadol hydrochloride
Tramadolum [INN-Latin]
Tramodol Hcl

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub>=350mg/kg (orally in mice)

# Update_Date:
2013-02-08 16:19:10 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Tramadol

# pKa_Isoelectric_Point:
9.41

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_1_ID:
4119

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2B6

# Phase_1_Metabolizing_Enzyme_3_ID:
6030

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2B6

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2B6
MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFRE
KYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNR
WKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIIC
SIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQE
INAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGT
ETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFS
DLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGAL
KKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKI
PPTYQIRFLPR

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P20813

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10961373	Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21.
10991912	Potschka H, Friderichs E, Loscher W: Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
1309873	Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan;260(1):275-85.
15509185	Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
16793069	Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology. 2006 Sep;51(3):651-8. Epub 2006 Jun 21.
17380034	Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007 Mar;103(3):253-60.
8955860	Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
OPRM1

# Drug_Target_1_GenBank_ID_Gene:
L25119

# Drug_Target_1_GenBank_ID_Protein:
452073

# Drug_Target_1_GeneCard_ID:
OPRM1

# Drug_Target_1_Gene_Name:
OPRM1

# Drug_Target_1_Gene_Sequence:
>1203 bp
ATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA
AGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC
CTGTCCGACCCATGCGGTCCGAACCGCACCAACCTGGGCGGGAGAGACAGCCTGTGCCCT
CCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG
TGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG
ATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC
AGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC
CTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC
TGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC
CGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT
GGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA
CTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTCGTGAAGATCTGTGTTTTCATC
TTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC
CTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC
ACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT
TACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG
CACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT
CTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT
GAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT
ACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC
TAA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10393893	Uhl GR, Sora I, Wang Z: The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7752-5.
7488213	Chuang TK, Killam KF Jr, Chuang LF, Kung HF, Sheng WS, Chao CC, Yu L, Chuang RY: Mu opioid receptor gene expression in immune cells. Biochem Biophys Res Commun. 1995 Nov 22;216(3):922-30.
7891175	Mestek A, Hurley JH, Bye LS, Campbell AD, Chen Y, Tian M, Liu J, Schulman H, Yu L: The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci. 1995 Mar;15(3 Pt 2):2396-406.
7905839	Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR: Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 1994 Jan 31;338(2):217-22.
7957926	Bare LA, Mansson E, Yang D: Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 1994 Nov 7;354(2):213-6.
9399694	Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D: Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry. 1997 Oct-Nov;2(6):490-4.
9689128	Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13.

# Drug_Target_1_HGNC_ID:
HGNC:8156

# Drug_Target_1_HPRD_ID:
02484

# Drug_Target_1_ID:
847

# Drug_Target_1_Locus:
6q24-q25

# Drug_Target_1_Molecular_Weight:
44780

# Drug_Target_1_Name:
Mu-type opioid receptor

# Drug_Target_1_Number_of_Residues:
400

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Alfentanil Pathway	SMP00413
Carfentanil Pathway	SMP00414
Codeine Pathway	SMP00405
Fentanyl Pathway	SMP00415
Heroin Pathway	SMP00407
Hydrocodone Pathway	SMP00411
Hydromorphone Pathway	SMP00410
Methadone Pathway	SMP00408
Morphine Pathway	SMP00406
Oxycodone Pathway	SMP00409
Oxymorphone Pathway	SMP00412
Remifentanil Pathway	SMP00416
Sufentanil Pathway	SMP00417

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Mu-type opioid receptor
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Receptor for beta-endorphin

# Drug_Target_1_SwissProt_ID:
P35372

# Drug_Target_1_SwissProt_Name:
OPRM_HUMAN

# Drug_Target_1_Synonyms:
MOR-1

# Drug_Target_1_Theoretical_pI:
8.29

# Drug_Target_1_Transmembrane_Regions:
67-96
106-123
146-165
196-211
237-259
283-305
314-330

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
11916794	Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, Shigematsu A: Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002 Apr;94(4):901-6, table of contents.
19341511	Berrocoso E, Mico JA: Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol. 2009 Sep;12(8):1033-44. Epub 2009 Apr 3.
8955860	Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SLC6A2

# Drug_Target_2_GenBank_ID_Gene:
M65105

# Drug_Target_2_GenBank_ID_Protein:
189258

# Drug_Target_2_GeneCard_ID:
SLC6A2

# Drug_Target_2_Gene_Name:
SLC6A2

# Drug_Target_2_Gene_Sequence:
>1854 bp
ATGCTTCTGGCGCGGATGAACCCGCAGGTGCAGCCCGAGAACAACGGGGCGGACACGGGT
CCAGAGCAGCCCCTTCGGGCGCGCAAAACTGCGGAGCTGCTGGTGGTGAAGGAGCGCAAC
GGCGTCCAGTGCCTGCTGGCGCCCCGCGACGGCGACGCGCAGCCCCGGGAGACCTGGGGC
AAGAAGATCGACTTCCTGCTGTCCGTAGTCGGCTTCGCAGTGGACCTGGCCAACGTGTGG
CGCTTCCCCTACCTCTGCTACAAGAACGGCGGCGGTGCCTTCTTGATCCCGTACACACTG
TTCCTTATCATCGCGGGGATGCCCCTGTTCTACATGGAGCTGGCTCTGGGACAGTACAAC
CGGGAGGGGGCTGCCACCGTTTGGAAAATCTGCCCATTCTTCAAAGGCGTTGGCTATGCT
GTCATCCTGATCGCCCTGTACGTTGGCTTCTACTACAACGTCATCATCGCCTGGTCACTC
TACTACCTCTTCTCCTCCTTCACCCTCAACCTGCCCTGGACCGACTGTGGCCACACCTGG
AACAGCCCCAACTGTACCGACCCCAAGCTCCTCAATGGCTCCGTGCTTGGCAACCACACC
AAGTACTCCAAGTACAAGTTCACGCCGGCAGCCGAGTTTTATGAGCGTGGTGTCCTGCAC
CTTCACGAGAGCAGCGGGATTCATGACATCGGCCTGCCCCAGTGGCAGCTCTTGCTCTGT
CTGATGGTCGTCGTCATCGTCTTGTATTTTAGCCTCTGGAAAGGGGTGAAGACATCAGGA
AAGGTGGTGTGGATCACAGCCACGCTGCCTTACTTCGTGCTGTTCGTGCTCCTGGTCCAT
GGCGTCACGCTGCCCGGAGCCTCCAATGGCATCAATGCCTACCTGCACATCGACTTCTAC
CGCTTGAAAGAGGCCACGGTATGGATTGATGCCGCAACTCAGATATTTTTTTCCTTGGGG
GCTGGATTTGGAGTATTGATTGCATTTGCCAGTTACAACAAATTTGACAACAACTGTTAC
AGGGATGCCCTGCTGACCAGCAGCATCAACTGTATCACCAGCTTCGTCTCTGGGTTCGCC
ATCTTCTCCATCCTTGGTTACATGGCCCATGAACACAAGGTCAACATTGAGGATGTGGCC
ACAGAAGGAGCTGGCCTAGTGTTCATCCTGTATCCAGAGGCCATTTCTACCCTGTCTGGA
TCTACATTCTGGGCTGTTGTGTTTTTCGTCATGCTCCTGGCGCTGGGCCTTGACAGCTCA
ATGGGAGGCATGGAGGCTGTCATCACGGGCCTGGCAGATGACTTCCAGGTCCTGAAGCGA
CACCGGAAACTCTTCACATTTGGCGTCACCTTCAGCACTTTCCTTCTCGCCCTGTTCTGC
ATAACCAAGGGTGGAATTTACGTCTTGACCCTCCTGGACACCTTTGCTGCGGGCACCTCC
ATCCTTTTTGCTGTCCTCATGGAAGCCATCGGAGTTTCCTGGTTTTATGGAGTGGACAGG
TTCAGCAACGACATCCAGCAGATGATGGGGTTCAGGCCGGGTCTATACTGGAGACTGTGC
TGGAAGTTCGTCAGTCCTGCCTTCCTCCTGTTCGTGGTTGTGGTCAGCATCATCAACTTC
AAGCCACTCACCTACGACGACTACATCTTCCCGCCCTGGGCCAACTGGGTGGGGTGGGGC
ATCGCCCTGTCCTCCATGGTCCTGGTGCCCATCTACGTCATCTATAAGTTCCTCAGCACG
CAGGGCTCTCTTTGGGAGAGACTGGCCTATGGCATCACGCCAGAGAACGAGCACCACCTG
GTGGCTCAGAGGGACATCAGACAGTTCCAGTTGCAACACTGGCTGGCCATCTGA

# Drug_Target_2_General_Function:
Involved in neurotransmitter:sodium symporter activity

# Drug_Target_2_General_References:
10684912	Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D: Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000 Feb 24;342(8):541-9.
11343649	Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, Caron MG: Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 2001 Apr;30(1):121-34.
2008212	Pacholczyk T, Blakely RD, Amara SG: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991 Mar 28;350(6316):350-4.
7488042	Porzgen P, Bonisch H, Bruss M: Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun. 1995 Oct 24;215(3):1145-50.

# Drug_Target_2_HGNC_ID:
HGNC:11048

# Drug_Target_2_HPRD_ID:
01232

# Drug_Target_2_ID:
540

# Drug_Target_2_Locus:
16q12.2

# Drug_Target_2_Molecular_Weight:
69333

# Drug_Target_2_Name:
Sodium-dependent noradrenaline transporter

# Drug_Target_2_Number_of_Residues:
617

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Desipramine Pathway	SMP00423
Disulfiram Pathway	SMP00429
Imipramine Pathway	SMP00422

# Drug_Target_2_Pfam_Domain_Function:
PF00209	SNF

# Drug_Target_2_Protein_Sequence:
>Sodium-dependent noradrenaline transporter
MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN
REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW
NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC
LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY
RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA
IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS
MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS
ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF
KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL
VAQRDIRQFQLQHWLAI

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals

# Drug_Target_2_SwissProt_ID:
P23975

# Drug_Target_2_SwissProt_Name:
SC6A2_HUMAN

# Drug_Target_2_Synonyms:
NET
Norepinephrine transporter

# Drug_Target_2_Theoretical_pI:
7.53

# Drug_Target_2_Transmembrane_Regions:
65-85
93-112
136-156
235-253
262-279
315-332
344-365
398-417
444-462
478-498
519-538
557-575

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
1596676	Driessen B, Reimann W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol. 1992 Jan;105(1):147-51.
16427041	Barann M, Urban B, Stamer U, Dorner Z, Bonisch H, Bruss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol. 2006 Feb 15;531(1-3):54-8. Epub 2006 Jan 19.
8955860	Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SLC6A4

# Drug_Target_3_GenBank_ID_Gene:
X70697

# Drug_Target_3_GenBank_ID_Protein:
36433

# Drug_Target_3_GeneCard_ID:
SLC6A4

# Drug_Target_3_Gene_Name:
SLC6A4

# Drug_Target_3_Gene_Sequence:
>1893 bp
ATGGAGACGACGCCCTTGAATTCTCAGAAGCAGCTATCAGCGTGTGAAGATGGAGAAGAT
TGTCAGGAAAACGGAGTTCTACAGAAGGTTGTTCCCACCCCAGGGGACAAAGTGGAGTCC
GGGCAAATATCCAATGGGTACTCAGCAGTTCCAAGTCCTGGTGCGGGAGATGACACACGG
CACTCTATCCCAGCGACCACCACCACCCTAGTGGCTGAGCTTCATCAAGGGGAACGGGAG
ACCTGGGGCAAGAAGGTGGATTTCCTTCTCTCAGTGATTGGCTATGCTGTGGACCTGGGC
AATGTCTGGCGCTTCCCCTACATATGTTACCAGAATGGAGGGGGGGCATTCCTCCTCCCC
TACACCATCATGGCCATTTTTGGGGGAATCCCGCTCTTTTACATGGAGCTCGCACTGGGA
CAGTACCACCGAAATGGATGCATTTCAATATGGAGGAAAATCTGCCCGATTTTCAAAGGG
ATTGGTTATGCCATCTGCATCATTGCCTTTTACATTGCTTCCTACTACAACACCATCATG
GCCTGGGCGCTATACTACCTCATCTCCTCCTTCACGGACCAGCTGCCCTGGACCAGCTGC
AAGAACTCCTGGAACACTGGCAACTGCACCAATTACTTCTCCGAGGACAACATCACCTGG
ACCCTCCATTCCACGTCCCCTGCTGAAGAATTTTACACGCGCCACGTCCTGCAGATCCAC
CGGTCTAAGGGGCTCCAGGACCTGGGGGGCATCAGCTGGCAGCTGGCCCTCTGCATCATG
CTGATCTTCACTGTTATCTACTTCAGCATCTGGAAAGGCGTCAAGACCTCTGGCAAGGTG
GTGTGGGTGACAGCCACCTTCCCTTATATCATCCTTTCTGTCCTGCTGGTGAGGGGTGCC
ACCCTCCCTGGAGCCTGGAGGGGTGTTCTCTTCTACTTGAAACCCAATTGGCAGAAACTC
CTGGAGACAGGGGTGTGGATAGATGCAGCCGCTCAGATCTTCTTCTCTCTTGGTCCGGGC
TTTGGGGTCCTGCTGGCTTTTGCTAGCTACAACAAGTTCAACAACAACTGCTACCAAGAT
GCCCTGGTGACCAGCGTGGTGAACTGCATGACGAGCTTCGTTTCGGGATTTGTCATCTTC
ACAGTGCTCGGTTACATGGCTGAGATGAGGAATGAAGATGTGTCTGAGGTGGCCAAAGAC
GCAGGTCCCAGCCTCCTCTTCATCACGTATGCAGAAGCGATAGCCAACATGCCAGCGTCC
ACTTTCTTTGCCATCATCTTCTTTCTGATGTTAATCACGCTGGGCTTGGACAGCACGTTT
GCAGGCTTGGAGGGGGTGATCACGGCTGTGCTGGATGAGTTCCCACACGTCTGGGCCAAG
CGCCGGGAGCGGTTCGTGCTCGCCGTGGTCATCACCTGCTTCTTTGGATCCCTGGTCACC
CTGACTTTTGGAGGGGCCTACGTGGTGAAGCTGCTGGAGGAGTATGCCACGGGGCCCGCA
GTGCTCACTGTCGCGCTGATCGAAGCAGTCGCTGTGTCTTGGTTCTATGGCATCACTCAG
TTCTGCAGGGACGTGAAGGAAATGCTCGGCTTCAGCCCGGGGTGGTTCTGGAGGATCTGC
TGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTCATCATTTGCAGTTTTCTGATGAGCCCG
CCACAACTACGACTTTTCCAATATAATTATCCTTACTGGAGTATCATCTTGGGTTACTGC
ATAGGAACCTCATCTTTCATTTGCATCCCCACATATATAGCTTATCGGTTGATCATCACT
CCAGGGACATTTAAAGAGCGTATTATTAAAAGTATTACCCCGGAGACACCAACAGAAATT
CCTTGTGGGGACATCCGCTTGAATGCTGTGTAA

# Drug_Target_3_General_Function:
Involved in serotonin:sodium symporter activity

# Drug_Target_3_General_References:
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
12869766	Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003 Jul 18;301(5631):386-9.
7681602	Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD: Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2542-6.
7684072	Lesch KP, Wolozin BL, Murphy DL, Reiderer P: Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem. 1993 Jun;60(6):2319-22.
8452685	Lesch KP, Wolozin BL, Estler HC, Murphy DL, Riederer P: Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect. 1993;91(1):67-72.

# Drug_Target_3_HGNC_ID:
HGNC:11050

# Drug_Target_3_HPRD_ID:
01640

# Drug_Target_3_ID:
824

# Drug_Target_3_Locus:
17q11.1-q12

# Drug_Target_3_Molecular_Weight:
70325

# Drug_Target_3_Name:
Sodium-dependent serotonin transporter

# Drug_Target_3_Number_of_Residues:
630

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Citalopram Pathway	SMP00424
Desipramine Pathway	SMP00423
Escitalopram Pathway	SMP00425
Fluoxetine Pathway	SMP00426
Imipramine Pathway	SMP00422

# Drug_Target_3_Pfam_Domain_Function:
PF00209	SNF
PF03491	5HT_transporter

# Drug_Target_3_Protein_Sequence:
>Sodium-dependent serotonin transporter
METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTR
HSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLP
YTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIM
AWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIH
RSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGA
TLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQD
ALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPAS
TFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVT
LTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRIC
WVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIIT
PGTFKERIIKSITPETPTEIPCGDIRLNAV

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Terminates the action of serotonine by its high affinity sodium-dependent reuptake into presynaptic terminals

# Drug_Target_3_SwissProt_ID:
P31645

# Drug_Target_3_SwissProt_Name:
SC6A4_HUMAN

# Drug_Target_3_Synonyms:
5HT transporter
5HTT

# Drug_Target_3_Theoretical_pI:
6.17

# Drug_Target_3_Transmembrane_Regions:
88-108
116-135
160-180
253-271
280-297
333-350
362-383
417-436
464-482
498-518
539-558
577-595

# Drug_Target_4_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
15105221	Ogata J, Minami K, Uezono Y, Okamoto T, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
16679816	Horishita T, Minami K, Uezono Y, Shiraishi M, Ogata J, Okamoto T, Shigematsu A: The tramadol metabolite, O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in Xenopus Oocytes. Pharmacology. 2006;77(2):93-9. Epub 2006 May 5.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
HTR2C

# Drug_Target_4_GenBank_ID_Gene:
M81778

# Drug_Target_4_GenBank_ID_Protein:
338028

# Drug_Target_4_GeneCard_ID:
HTR2C

# Drug_Target_4_Gene_Name:
HTR2C

# Drug_Target_4_Gene_Sequence:
>1377 bp
ATGGTGAACCTGAGGAATGCGGTGCATTCATTCCTTGTGCACCTAATTGGCCTATTGGTT
TGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACC
TCCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATC
GTCATCATAATAATCATGACAATAGGTGGCAACATCCTTGTGATCATGGCAGTAAGCATG
GAAAAGAAACTGCACAATGCCACCAATTACTTCTTAATGTCCCTAGCCATTGCTGATATG
CTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCTGGCAATCCTTTATGATTATGTCTGG
CCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTTTATTTTCAACAGCG
TCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAGCAATACGTAATCCTATT
GAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCA
ATTTCTATAGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTG
TTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTC
GTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTT
CTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGT
CTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCT
AACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATG
CAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTT
CTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCC
TGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGT
TCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCC
AACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGA
GTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAAT
GAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAAT
TTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGA

# Drug_Target_4_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_4_General_References:
10206230	Samochowiec J, Smolka M, Winterer G, Rommelspacher H, Schmidt LG, Sander T: Association analysis between a Cys23Ser substitution polymorphism of the human 5-HT2c receptor gene and neuronal hyperexcitability. Am J Med Genet. 1999 Apr 16;88(2):126-30.
10391209	Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.
10581480	Marshall SE, Bird TG, Hart K, Welsh KI: Unified approach to the analysis of genetic variation in serotonergic pathways. Am J Med Genet. 1999 Dec 15;88(6):621-7.
11150294	Becamel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, Lubbert H, Ullmer C: Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. J Biol Chem. 2001 Apr 20;276(16):12974-82. Epub 2001 Jan 9.
1722404	Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S: Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1469-78.
7557992	Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, Goldman D: Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics. 1995 May 20;27(2):274-9.
7895773	Stam NJ, Vanderheyden P, van Alebeek C, Klomp J, de Boer T, van Delft AM, Olijve W: Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT2C receptor. Eur J Pharmacol. 1994 Nov 15;269(3):339-48.
8812491	Xie E, Zhu L, Zhao L, Chang LS: The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant. Genomics. 1996 Aug 1;35(3):551-61.
9928237	Niswender CM, Sanders-Bush E, Emeson RB: Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci. 1998 Dec 15;861:38-48.

# Drug_Target_4_HGNC_ID:
HGNC:5295

# Drug_Target_4_HPRD_ID:
02429

# Drug_Target_4_ID:
590

# Drug_Target_4_Locus:
Xq24

# Drug_Target_4_Molecular_Weight:
51822

# Drug_Target_4_Name:
5-hydroxytryptamine 2C receptor

# Drug_Target_4_Number_of_Residues:
458

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_4_Protein_Sequence:
>5-hydroxytryptamine 2C receptor
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI
VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW
PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA
ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV
LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM
QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC
SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN
EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system

# Drug_Target_4_SwissProt_ID:
P28335

# Drug_Target_4_SwissProt_Name:
5HT2C_HUMAN

# Drug_Target_4_Synonyms:
5- HT2C
5-HT-2C
5-HTR2C
5HT-1C
Serotonin receptor 2C

# Drug_Target_4_Theoretical_pI:
9.11

# Drug_Target_4_Transmembrane_Regions:
53-78
90-110
128-150
171-193
214-235
312-333
349-371

# Drug_Target_5_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
12570923	Sun HL, Zheng JW, Wang K, Liu RK, Liang JH: Tramadol reduces the 5-HTP-induced head-twitch response in mice via the activation of mu and kappa opioid receptors. Life Sci. 2003 Jan 31;72(11):1221-30.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
OPRK1

# Drug_Target_5_GenBank_ID_Gene:
U11053

# Drug_Target_5_GenBank_ID_Protein:
532060

# Drug_Target_5_GeneCard_ID:
OPRK1

# Drug_Target_5_Gene_Name:
OPRK1

# Drug_Target_5_Gene_Sequence:
>1143 bp
ATGGAATCCCCGATTCAGATCTTCCGCGGGGAGCCTGGCCCTACCTGCGCCCCGAGCGCC
TGCCTGCCCCCCAACAGCAGCGCCTGGTTTCCCGGCTGGGCCGAGCCCGACAGCAACGGC
AGCGCCGGCTCGGAGGACGCGCAGCTGGAGCCCGCGCACATCTCCCCGGCCATCCCGGTC
ATCATCACGGCGGTCTACTCCGTAGTGTTCGTCGTGGGCTTGGTGGGCAACTCGCTGGTC
ATGTTCGTGATCATCCGATACACAAAGATGAAGACAGCAACCAACATTTACATATTTAAC
CTGGCTTTGGCAGATGCTTTAGTTACTACAACCATGCCCTTTCAGAGTACGGTCTACTTG
ATGAATTCCTGGCCTTTTGGGGATGTGCTGTGCAAGATAGTAATTTCCATTGATTACTAC
AACATGTTCACCAGCATCTTCACCTTGACCATGATGAGCGTGGACCGCTACATTGCCGTG
TGCCACCCCGTGAAGGCTTTGGACTTCCGCACACCCTTGAAGGCAAAGATCATCAATATC
TGCATCTGGCTGCTGTCGTCATCTGTTGGCATCTCTGCAATAGTCCTTGGAGGCACCAAA
GTCAGGGAAGACGTCGATGTCATTGAGTGCTCCTTGCAGTTCCCAGATGATGACTACTCC
TGGTGGGACCTCTTCATGAAGATCTGCGTCTTCATCTTTGCCTTCGTGATCCCTGTCCTC
ATCATCATCGTCTGCTACACCCTGATGATCCTGCGTCTCAAGAGCGTCCGGCTCCTTTCT
GGCTCCCGAGAGAAAGATCGCAACCTGCGTAGGATCACCAGACTGGTCCTGGTGGTGGTG
GCGGTTTTCGTCGTCTGCTGGACTCCCATTCACATATTCATCCTGGTGGAGGCTCTGGGG
AGCACCTCCCACAGCACAGCTGCTCTCTCCAGCTATTACTTCTGCATCGCCTTAGGCTAT
ACCAACAGTAGCCTGAATCCCATTCTCTACGCCTTTCTTGATGAAAACTTCAAGCGGTGT
TTCCGGGACTTCTGCTTTCCACTGAAGATGAGGATGGAGCGGCAGAGCACTAGCAGAGTC
CGAAATACAGTTCAGGATCCTGCTTACCTGAGGGACATCGATGGGATGAATAAACCAGTA
TGA

# Drug_Target_5_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_5_General_References:
12004055	Li JG, Chen C, Liu-Chen LY: Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human kappa opioid receptor by enhancing its recycling rate. J Biol Chem. 2002 Jul 26;277(30):27545-52. Epub 2002 May 9.
7624359	Simonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattei MG, Charron G, Bloch B, Kieffer B: kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7006-10.
7869844	Zhu J, Chen C, Xue JC, Kunapuli S, DeRiel JK, Liu-Chen LY: Cloning of a human kappa opioid receptor from the brain. Life Sci. 1995;56(9):PL201-7.
7929306	Wang JB, Johnson PS, Wu JM, Wang WF, Uhl GR: Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras. J Biol Chem. 1994 Oct 21;269(42):25966-9.
8060324	Mansson E, Bare L, Yang D: Isolation of a human kappa opioid receptor cDNA from placenta. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1431-7.

# Drug_Target_5_HGNC_ID:
HGNC:8154

# Drug_Target_5_HPRD_ID:
01309

# Drug_Target_5_ID:
696

# Drug_Target_5_Locus:
8q11.2

# Drug_Target_5_Molecular_Weight:
42646

# Drug_Target_5_Name:
Kappa-type opioid receptor

# Drug_Target_5_Number_of_Residues:
380

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_5_Protein_Sequence:
>Kappa-type opioid receptor
MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPV
IITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYL
MNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINI
CIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVL
IIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALG
STSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRV
RNTVQDPAYLRDIDGMNKPV

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Receptor for dynorphins. May play a role in arousal and regulation of autonomic and neuroendocrine functions

# Drug_Target_5_SwissProt_ID:
P41145

# Drug_Target_5_SwissProt_Name:
OPRK_HUMAN

# Drug_Target_5_Synonyms:
KOR-1

# Drug_Target_5_Theoretical_pI:
7.79

# Drug_Target_5_Transmembrane_Regions:
59-85
96-117
133-154
174-196
223-247
276-299
312-333

# Drug_Target_6_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
19027293	Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM: Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
OPRD1

# Drug_Target_6_GenBank_ID_Gene:
U07882

# Drug_Target_6_GenBank_ID_Protein:
27545517

# Drug_Target_6_GeneCard_ID:
OPRD1

# Drug_Target_6_Gene_Name:
OPRD1

# Drug_Target_6_Gene_Sequence:
>1119 bp
ATGGAACCGGCCCCCTCCGCCGGCGCCGAGCTGCAGCCCCCGCTCTTCGCCAACGCCTCG
GACGCCTACCCTAGCGCCTTCCCCAGCGCTGGCGCCAATGCGTCGGGGCCGCCAGGCGCG
CGGAGCGCCTCGTCCCTCGCCCTGGCAATCGCCATCACCGCGCTCTACTCGGCCGTGTGC
GCCGTGGGGCTGCTGGGCAACGTGCTTGTCATGTTCGGCATCGTCCGGTACACTAAGATG
AAGACGGCCACCAACATCTACATCTTCAACCTGGCCTTAGCCGATGCGCTGGCCACCAGC
ACGCTGCCTTTCCAGAGTGCCAAGTACCTGATGGAGACGTGGCCCTTCGGCGAGCTGCTC
TGCAAGGCTGTGCTCTCCATCGACTACTACAATATGTTCACCAGCATCTTCACGCTCACC
ATGATGAGTGTTGACCGCTACATCGCTGTCTGCCACCCTGTCAAGGCCCTGGACTTCCGC
ACGCCTGCCAAGGCCAAGCTGATCAACATCTGTATCTGGGTCCTGGCCTCAGGCGTTGGC
GTGCCCATCATGGTCATGGCTGTGACCCGTCCCCGGGACGGGGCAGTGGTGTGCATGCTC
CAGTTCCCCAGCCCCAGCTGGTACTGGGACACGGTGACCAAGATCTGCGTGTTCCTCTTC
GCCTTCGTGGTGCCCATCCTCATCATCACCGTGTGCTATGGCCTCATGCTGCTGCGCCTG
CGCAGTGTGCGCCTGCTGTCGGGCTCCAAGGAGAAGGACCGCAGCCTGCGGCGCATCACG
CGCATGGTGCTGGTGGTTGTGGGCGCCTTCGTGGTGTGTTGGGCGCCCATCCACATCTTC
GTCATCGTCTGGACGCTGGTGGACATCGACCGGCGCGACCCGCTGGTGGTGGCTGCGCTG
CACCTGTGCATCGCGCTGGGCTACGCCAATAGCAGCCTCAACCCCGTGCTCTACGCTTTC
CTCGACGAGAACTTCAAGCGCTGCTTCCGCCAGCTCTGCCGCAAGCCCTGCGGCCGCCCA
GACCCCAGCAGCTTCAGCCGCGCCCGCGAAGCCACGGCCCGCGAGCGTGTCACCGCCTGC
ACCCCGTCCGATGGTCCCGGCGGTGGCGCTGCCGCCTGA

# Drug_Target_6_General_Function:
Involved in delta-opioid receptor activity

# Drug_Target_6_General_References:
10982041	Gelernter J, Kranzler HR: Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Hum Genet. 2000 Jul;107(1):86-8.
7808419	Simonin F, Befort K, Gaveriaux-Ruff C, Matthes H, Nappey V, Lannes B, Micheletti G, Kieffer B: The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol Pharmacol. 1994 Dec;46(6):1015-21.
8201839	Knapp RJ, Malatynska E, Fang L, Li X, Babin E, Nguyen M, Santoro G, Varga EV, Hruby VJ, Roeske WR, et al.: Identification of a human delta opioid receptor: cloning and expression. Life Sci. 1994;54(25):PL463-9.

# Drug_Target_6_HGNC_ID:
HGNC:8153

# Drug_Target_6_HPRD_ID:
01308

# Drug_Target_6_ID:
467

# Drug_Target_6_Locus:
1p36.1-p34.3

# Drug_Target_6_Molecular_Weight:
40413

# Drug_Target_6_Name:
Delta-type opioid receptor

# Drug_Target_6_Number_of_Residues:
372

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_6_Protein_Sequence:
>Delta-type opioid receptor
MEPAPSAGAELQPPLFANASDAYPSAFPSAGANASGPPGARSASSLALAIAITALYSAVC
AVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELL
CKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVG
VPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRL
RSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAAL
HLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTAC
TPSDGPGGGAAA

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Highly stereoselective. receptor for enkephalins

# Drug_Target_6_SwissProt_ID:
P41143

# Drug_Target_6_SwissProt_Name:
OPRD_HUMAN

# Drug_Target_6_Synonyms:
DOR-1

# Drug_Target_6_Theoretical_pI:
9.17

# Drug_Target_6_Transmembrane_Regions:
46-75
85-102
125-144
175-190
216-238
262-284
294-310

# Drug_Target_7_Cellular_Location:
Cell membrane
multi-pass membrane protein. Enriched in post-synaptic plasma membrane and post-synap

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
15845694	Hara K, Minami K, Sata T: The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg. 2005 May;100(5):1400-5, table of contents.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
GRIN3A

# Drug_Target_7_GenBank_ID_Gene:
AJ416950

# Drug_Target_7_GenBank_ID_Protein:
20372905

# Drug_Target_7_GeneCard_ID:
GRIN3A

# Drug_Target_7_Gene_Name:
GRIN3A

# Drug_Target_7_Gene_Sequence:
>3348 bp
ATGAGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGGTCTGTCTGCTGTTGCCGCCGCCC
TGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAGCCCTGCCAGATC
CTCAAGCGCATCGGGCACGCGGTGAGGGTGGGCGCGGTGCACTTGCAGCCCTGGACCACC
GCCCCCCGCGCGGCCAGCCGCGCTCCGGACGACAGCCGAGCAGGAGCCCAGAGGGATGAG
CCGGAGCCAGGGACTAGGCGGTCCCCGGCGCCCTCGCCGGGCGCACGCTGGTTGGGGAGC
ACCCTGCATGGCCGGGGGCCGCCGGGCTCCCGTAAGCCCGGGGAGGGCGCCAGGGCGGAG
GCCCTGTGGCCACGGGACGCCCTCCTATTTGCCGTGGACAACCTGAACCGCGTGGAAGGG
CTGCTACCCTACAACCTGTCTTTGGAAGTAGTGATGGCCATCGAGGCAGGCCTGGGCGAT
CTGCCACTTTTGCCCTTCTCCTCCCCTAGTTCGCCATGGAGCAGTGACCCTTTCTCCTTC
CTGCAAAGTGTGTGCCATACCGTGGTGGTGCAAGGGGTGTCGGCGCTGCTCGCCTTCCCC
CAGAGCCAGGGCGAAATGATGGAGCTCGACTTGGTCAGCTTAGTCCTGCACATTCCAGTG
ATCAGCATCGTGCGCCACGAGTTTCCGCGGGAGAGTCAGAATCCCCTTCACCTACAACTG
AGTTTAGAAAATTCATTAAGTTCTGATGCTGATGTCACTGTCTCAATCCTGACCATGAAC
AACTGGTACAATTTTAGCTTGTTGCTGTGCCAGGAAGACTGGAACATCACCGACTTCCTC
CTCCTTACCCAGAATAATTCCAAGTTCCACCTTGGTTCTATCATCAACATCACCGCTAAC
CTCCCCTCCACCCAGGACCTCTTGAGCTTCCTACAGATCCAGCTTGAGAGTATTAAGAAC
AGCACACCCACAGTGGTGATGTTTGGCTGCGACATGGAAAGTATCCGGCGGATTTTCGAA
ATTACAACCCAGTTTGGGGTCATGCCCCCTGAACTTCGTTGGGTGCTGGGAGATTCCCAG
AATATGGAGGAACTGAGGACAGAGGGTCTGCCCTTAGGACTCATTGCTCATGGAAAAACA
ACACAGTCTGTCTTTGAGCACTACGTACAAGATGCTATGGAGCTGGTCGCAAGAGCTGTA
GCCACAGCCACCATGATCCAACCAGAACTTGCTCTCATTCCCAGCACGATGAACTGCATG
GAGGTGGAAACTACAAATCTCACTTCAGGACAATATTTATCAAGGTTTCTAGCCAATACC
ACTTTCAGAGGCCTCAGTGGTTCCATCAGAGTAAAAGGTTCCACCATCGTCAGCTCAGAA
AACAACTTTTTCATCTGGAATCTTCAACATGACCCCATGGGAAAGCCAATGTGGACCCGC
TTGGGCAGCTGGCAGGGGAGAAAGATTGTCATGGACTATGGAATATGGCCAGAGCAGGCC
CAGAGACACAAAACCCACTTCCAACATCCAAGTAAGCTACACTTGAGAGTGGTTACCCTG
ATTGAGCATCCTTTTGTCTTCACAAGGGAGGTAGATGATGAAGGCTTGTGCCCTGCTGGC
CAACTCTGTCTAGACCCCATGACTAATGACTCTTCCACACTGGACAGCCTTTTTAGCAGC
CTCCATAGCAGTAATGATACAGTGCCCATTAAATTCAAGAAGTGCTGCTATGGATATTGC
ATTGATCTGCTGGAAAAGATAGCAGAAGACATGAACTTTGACTTCGACCTCTATATTGTA
GGGGATGGAAAGTATGGAGCCTGGAAAAATGGGCACTGGACTGGGCTAGTGGGTGATCTC
CTGAGAGGGACTGCCCACATGGCAGTCACTTCCTTTAGCATCAATACTGCACGGAGCCAG
GTGATAGATTTCACCAGCCCTTTCTTCTCCACCAGCTTGGGCATCTTAGTGAGGACCCGA
GATACAGCAGCTCCCATTGGAGCCTTCATGTGGCCACTCCACTGGACAATGTGGCTGGGG
ATTTTTGTGGCTCTGCACATCACTGCCGTCTTCCTCACTCTGTATGAATGGAAGAGTCCA
TTTGGTTTGACTCCCAAGGGGCGAAATAGAAGTAAAGTCTTCTCCTTTTCTTCAGCCTTG
AACATCTGTTATGCCCTCTTGTTTGGCAGAACAGTGGCCATCAAACCTCCAAAATGTTGG
ACTGGAAGGTTTCTAATGAACCTTTGGGCCATTTTCTGTATGTTTTGCCTTTCCACATAC
ACGGCAAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATA
CATGACCCCAAGTTACATCATCCTTCCCAAGGATTCCGCTTTGGAACTGTCCGAGAAAGC
AGTGCTGAAGATTATGTGAGACAAAGTTTCCCAGAGATGCATGAATATATGAGAAGGTAC
AATGTTCCAGCCACCCCTGATGGAGTGGAGTATCTGAAGAACAATCCAGAGAAACTAGAC
GCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAA
CTTCTCACTGTGGGGAAGCCATTTGCCATAGAAGGATACGGCATTGGCCTCCCACCCAAC
TCTCCATTGACCGCCAACATATCCGAGCTAATCAGTCAATACAAGTCACATGGGTTTATG
GATATGCTCCATGACAAGTGGTACAGGGTGGTTCCCTGTGGCAAGAGAAGTTTTGCTGTC
ACGGAGACTTTGCAAATGGGCATCAAACACTTCTCTGGGCTCTTTGTGCTGCTGTGCATT
GGATTTGGTCTGTCCATTTTGACCACCATTGGTGAGCACATAGTATACAGGCTGCTGCTA
CCACGAATCAAAAACAAATCCAAGCTGCAATACTGGCTCCACACCAGCCAGAGATTACAC
AGAGCAATAAATACATCATTTATAGAGGAAAAGCAGCAGCATTTCAAGACCAAACGTGTG
GAAAAGAGGTCTAATGTGGGACCCCGTCAGCTTACCGTATGGAATACTTCCAATCTGAGT
CATGACAACCGACGGAAATACATCTTTAGTGATGAGGAAGGACAAAACCAGCTGGGCATC
CGGATCCACCAGGACATCCCCCTCCCTCCAAGGAGAAGAGAGCTCCCTGCCTTGCGGACC
ACCAATGGGAAAGCAGACTCCCTAAATGTATCTCGGAACTCAGTGATGCAGGAACTCTCA
GAGCTCGAGAAGCAGATTCAGGTGATCCGTCAGGAGCTGCAGCTGGCTGTGAGCAGGAAA
ACGGAGCTGGAGGAGTATCAAAGGACAAGTCGGACTTGTGAGTCCTAG

# Drug_Target_7_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_7_General_References:
11735224	Andersson O, Stenqvist A, Attersand A, von Euler G: Nucleotide sequence, genomic organization, and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. Genomics. 2001 Dec;78(3):178-84.
11853319	Nagase T, Kikuno R, Ohara O: Prediction of the coding sequences of unidentified human genes. XXII. The complete sequences of 50 new cDNA clones which code for large proteins. DNA Res. 2001 Dec 31;8(6):319-27.
11880201	Eriksson M, Nilsson A, Froelich-Fabre S, Akesson E, Dunker J, Seiger A, Folkesson R, Benedikz E, Sundstrom E: Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A. Neurosci Lett. 2002 Mar 22;321(3):177-81.

# Drug_Target_7_HGNC_ID:
HGNC:16767

# Drug_Target_7_HPRD_ID:
09443

# Drug_Target_7_ID:
706

# Drug_Target_7_Locus:
9q31.1

# Drug_Target_7_Molecular_Weight:
125597

# Drug_Target_7_Name:
Glutamate [NMDA] receptor subunit 3A

# Drug_Target_7_Number_of_Residues:
1115

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Methadone Pathway	SMP00408

# Drug_Target_7_Pfam_Domain_Function:
PF00060	Lig_chan

# Drug_Target_7_Protein_Sequence:
>Glutamate [NMDA] receptor subunit 3A precursor
MRRLSLWWLLSRVCLLLPPPCALVLAGVPSSSSHPQPCQILKRIGHAVRVGAVHLQPWTT
APRAASRAPDDSRAGAQRDEPEPGTRRSPAPSPGARWLGSTLHGRGPPGSRKPGEGARAE
ALWPRDALLFAVDNLNRVEGLLPYNLSLEVVMAIEAGLGDLPLLPFSSPSSPWSSDPFSF
LQSVCHTVVVQGVSALLAFPQSQGEMMELDLVSLVLHIPVISIVRHEFPRESQNPLHLQL
SLENSLSSDADVTVSILTMNNWYNFSLLLCQEDWNITDFLLLTQNNSKFHLGSIINITAN
LPSTQDLLSFLQIQLESIKNSTPTVVMFGCDMESIRRIFEITTQFGVMPPELRWVLGDSQ
NMEELRTEGLPLGLIAHGKTTQSVFEHYVQDAMELVARAVATATMIQPELALIPSTMNCM
EVETTNLTSGQYLSRFLANTTFRGLSGSIRVKGSTIVSSENNFFIWNLQHDPMGKPMWTR
LGSWQGRKIVMDYGIWPEQAQRHKTHFQHPSKLHLRVVTLIEHPFVFTREVDDEGLCPAG
QLCLDPMTNDSSTLDSLFSSLHSSNDTVPIKFKKCCYGYCIDLLEKIAEDMNFDFDLYIV
GDGKYGAWKNGHWTGLVGDLLRGTAHMAVTSFSINTARSQVIDFTSPFFSTSLGILVRTR
DTAAPIGAFMWPLHWTMWLGIFVALHITAVFLTLYEWKSPFGLTPKGRNRSKVFSFSSAL
NICYALLFGRTVAIKPPKCWTGRFLMNLWAIFCMFCLSTYTANLAAVMVGEKIYEELSGI
HDPKLHHPSQGFRFGTVRESSAEDYVRQSFPEMHEYMRRYNVPATPDGVEYLKNNPEKLD
AFIMDKALLDYEVSIDADCKLLTVGKPFAIEGYGIGLPPNSPLTANISELISQYKSHGFM
DMLHDKWYRVVPCGKRSFAVTETLQMGIKHFSGLFVLLCIGFGLSILTTIGEHIVYRLLL
PRIKNKSKLQYWLHTSQRLHRAINTSFIEEKQQHFKTKRVEKRSNVGPRQLTVWNTSNLS
HDNRRKYIFSDEEGQNQLGIRIHQDIPLPPRRRELPALRTTNGKADSLNVSRNSVMQELS
ELEKQIQVIRQELQLAVSRKTELEEYQRTSRTCES

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
1-23

# Drug_Target_7_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism

# Drug_Target_7_SwissProt_ID:
Q8TCU5

# Drug_Target_7_SwissProt_Name:
NMD3A_HUMAN

# Drug_Target_7_Synonyms:
Glutamate receptor subunit 3A precursor
N-methyl-D-aspartate receptor subtype NR3A
NMDAR-L

# Drug_Target_7_Theoretical_pI:
7.81

# Drug_Target_7_Transmembrane_Regions:
675-695
749-769
931-951

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
12010769	Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A, Shibuya I: Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha 7 receptors. Br J Pharmacol. 2002 May;136(2):207-16.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
CHRFAM7A

# Drug_Target_8_GenBank_ID_Gene:
AY641831

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
CHRFAM7A

# Drug_Target_8_Gene_Sequence:
>87 bp
GGATAACAGTCTTACTCTCTCTTACCGTCTTCATGCTGCTCGTGGCTGAGATCATGCCCG
CAACATCCGATTCGGTACCATTGATAG

# Drug_Target_8_General_Function:
Involved in neurotransmitter receptor activity

# Drug_Target_8_General_References:
Not Available

# Drug_Target_8_HGNC_ID:
HGNC:15781

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
5878

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
2988

# Drug_Target_8_Name:
Alpha-7 nicotinic cholinergic receptor subunit

# Drug_Target_8_Number_of_Residues:
28

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF02932	Neur_chan_memb

# Drug_Target_8_Protein_Sequence:
>Alpha-7 nicotinic cholinergic receptor subunit
ITVLLSLTVFMLLVAEIMPATSDSVPLI

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
Q693P7

# Drug_Target_8_SwissProt_Name:
Q693P7_HUMAN

# Drug_Target_8_Synonyms:
Not Available

# Drug_Target_8_Theoretical_pI:
3.55

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
11561087	Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A: Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther. 2001 Oct;299(1):255-60.
12401609	Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, Shigematsu A: The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg. 2002 Nov;95(5):1269-73, table of contents.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
CHRM3

# Drug_Target_9_GenBank_ID_Gene:
X15266

# Drug_Target_9_GenBank_ID_Protein:
32324

# Drug_Target_9_GeneCard_ID:
CHRM3

# Drug_Target_9_Gene_Name:
CHRM3

# Drug_Target_9_Gene_Sequence:
>1773 bp
ATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG
ATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC
AATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG
GGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG
GTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG
ACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT
TCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC
TGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG
GTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA
ACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG
GCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG
TGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT
TATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG
CGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT
GTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG
AAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG
AAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT
GATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG
ACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC
ACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC
TTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT
CCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT
TCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA
GCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG
ATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC
ATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC
ATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC
CCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG
TGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT
TTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG

# Drug_Target_9_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_9_General_References:
11238933	Speek M: Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol. 2001 Mar;21(6):1973-85.
3272174	Bonner TI, Young AC, Brann MR, Buckley NJ: Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1988 Jul;1(5):403-10.
3443095	Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.

# Drug_Target_9_HGNC_ID:
HGNC:1952

# Drug_Target_9_HPRD_ID:
00329

# Drug_Target_9_ID:
51

# Drug_Target_9_Locus:
1q43

# Drug_Target_9_Molecular_Weight:
66129

# Drug_Target_9_Name:
Muscarinic acetylcholine receptor M3

# Drug_Target_9_Number_of_Residues:
590

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_9_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_9_Protein_Sequence:
>Muscarinic acetylcholine receptor M3
MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL
GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI
SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR
TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF
YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM
KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE
TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF
PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR
MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN
PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover

# Drug_Target_9_SwissProt_ID:
P20309

# Drug_Target_9_SwissProt_Name:
ACM3_HUMAN

# Drug_Target_9_Synonyms:
Not Available

# Drug_Target_9_Theoretical_pI:
9.62

# Drug_Target_9_Transmembrane_Regions:
68-91
105-125
143-164
185-207
230-252
493-513
528-547

#END_DRUGCARD DB00193
